vs
Side-by-side financial comparison of BridgeBio Pharma, Inc. (BBIO) and PagerDuty, Inc. (PD). Click either name above to swap in a different company.
BridgeBio Pharma, Inc. is the larger business by last-quarter revenue ($154.2M vs $124.5M, roughly 1.2× PagerDuty, Inc.). PagerDuty, Inc. runs the higher net margin — 129.7% vs -126.2%, a 256.0% gap on every dollar of revenue. On growth, BridgeBio Pharma, Inc. posted the faster year-over-year revenue change (2521.2% vs 4.7%). PagerDuty, Inc. produced more free cash flow last quarter ($24.1M vs $-56.5M).
Brent Saunders is an American biopharma executive and entrepreneur who is the chairman and CEO of the health company Bausch & Lomb. He helped lead various mergers and acquisitions, including the mergers between Merck and Schering-Plough, the acquisition of Bausch + Lomb by Valeant Pharmaceuticals, and the $63 billion acquisition of Allergan by Abbvie. He founded the special-purpose acquisition company (SPAC) Vesper Healthcare Acquisition. Saunders is also executive chairman of medical aesthet...
PagerDuty, Inc. is an American cloud computing company specializing in a SaaS incident management platform for IT operations departments.
BBIO vs PD — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $154.2M | $124.5M |
| Net Profit | $-194.6M | $161.6M |
| Gross Margin | 94.7% | 85.3% |
| Operating Margin | -90.5% | 6.5% |
| Net Margin | -126.2% | 129.7% |
| Revenue YoY | 2521.2% | 4.7% |
| Net Profit YoY | 27.2% | 2827.7% |
| EPS (diluted) | $-1.00 | $1.69 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $154.2M | $124.5M | ||
| Q3 25 | $120.7M | $123.4M | ||
| Q2 25 | $110.6M | $119.8M | ||
| Q1 25 | $116.6M | $121.4M | ||
| Q4 24 | — | $118.9M | ||
| Q3 24 | — | $115.9M | ||
| Q2 24 | — | $111.2M | ||
| Q1 24 | $211.1M | $111.1M |
| Q4 25 | $-194.6M | $161.6M | ||
| Q3 25 | $-184.9M | $9.6M | ||
| Q2 25 | $-183.8M | $-7.2M | ||
| Q1 25 | $-169.6M | $-8.8M | ||
| Q4 24 | — | $-5.9M | ||
| Q3 24 | — | $-10.9M | ||
| Q2 24 | — | $-17.1M | ||
| Q1 24 | $-36.2M | $-28.2M |
| Q4 25 | 94.7% | 85.3% | ||
| Q3 25 | 94.6% | 84.6% | ||
| Q2 25 | 96.7% | 84.0% | ||
| Q1 25 | 97.7% | 83.6% | ||
| Q4 24 | — | 83.0% | ||
| Q3 24 | — | 82.7% | ||
| Q2 24 | — | 82.6% | ||
| Q1 24 | 99.7% | 81.7% |
| Q4 25 | -90.5% | 6.5% | ||
| Q3 25 | -120.3% | 2.9% | ||
| Q2 25 | -121.4% | -8.6% | ||
| Q1 25 | -89.5% | -9.6% | ||
| Q4 24 | — | -8.7% | ||
| Q3 24 | — | -13.8% | ||
| Q2 24 | — | -19.5% | ||
| Q1 24 | 0.2% | -30.1% |
| Q4 25 | -126.2% | 129.7% | ||
| Q3 25 | -153.2% | 7.8% | ||
| Q2 25 | -166.2% | -6.0% | ||
| Q1 25 | -145.4% | -7.2% | ||
| Q4 24 | — | -5.0% | ||
| Q3 24 | — | -9.4% | ||
| Q2 24 | — | -15.4% | ||
| Q1 24 | -17.1% | -25.3% |
| Q4 25 | $-1.00 | $1.69 | ||
| Q3 25 | $-0.95 | $0.10 | ||
| Q2 25 | $-0.95 | $-0.07 | ||
| Q1 25 | $-0.88 | $-0.12 | ||
| Q4 24 | — | $-0.07 | ||
| Q3 24 | — | $-0.14 | ||
| Q2 24 | — | $-0.26 | ||
| Q1 24 | $-0.20 | $-0.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $570.1M | $547.8M |
| Total DebtLower is stronger | $2.0B | — |
| Stockholders' EquityBook value | $-2.1B | $320.5M |
| Total Assets | $936.0M | $1.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $570.1M | $547.8M | ||
| Q3 25 | $643.0M | $567.9M | ||
| Q2 25 | $756.9M | $597.1M | ||
| Q1 25 | $540.6M | $570.8M | ||
| Q4 24 | — | $542.2M | ||
| Q3 24 | — | $599.3M | ||
| Q2 24 | — | $592.8M | ||
| Q1 24 | $519.7M | $571.2M |
| Q4 25 | $2.0B | — | ||
| Q3 25 | $2.0B | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $484.5M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $489.5M |
| Q4 25 | $-2.1B | $320.5M | ||
| Q3 25 | $-1.9B | $180.7M | ||
| Q2 25 | $-1.8B | $145.7M | ||
| Q1 25 | $-1.6B | $129.8M | ||
| Q4 24 | — | $111.6M | ||
| Q3 24 | — | $164.7M | ||
| Q2 24 | — | $174.0M | ||
| Q1 24 | $-1.0B | $171.6M |
| Q4 25 | $936.0M | $1.0B | ||
| Q3 25 | $998.3M | $891.5M | ||
| Q2 25 | $1.1B | $926.8M | ||
| Q1 25 | $881.6M | $927.3M | ||
| Q4 24 | — | $866.8M | ||
| Q3 24 | — | $916.0M | ||
| Q2 24 | — | $924.0M | ||
| Q1 24 | $849.3M | $925.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 3.73× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 2.85× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-56.4M | $24.8M |
| Free Cash FlowOCF − Capex | $-56.5M | $24.1M |
| FCF MarginFCF / Revenue | -36.6% | 19.3% |
| Capex IntensityCapex / Revenue | 0.0% | 0.6% |
| Cash ConversionOCF / Net Profit | — | 0.15× |
| TTM Free Cash FlowTrailing 4 quarters | — | $117.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-56.4M | $24.8M | ||
| Q3 25 | $-109.6M | $34.0M | ||
| Q2 25 | $-80.7M | $30.7M | ||
| Q1 25 | $-199.2M | $31.4M | ||
| Q4 24 | — | $22.1M | ||
| Q3 24 | — | $35.8M | ||
| Q2 24 | — | $28.6M | ||
| Q1 24 | $-219.5M | $22.2M |
| Q4 25 | $-56.5M | $24.1M | ||
| Q3 25 | $-110.0M | $33.1M | ||
| Q2 25 | $-81.3M | $30.2M | ||
| Q1 25 | — | $30.3M | ||
| Q4 24 | — | $21.5M | ||
| Q3 24 | — | $35.1M | ||
| Q2 24 | — | $28.2M | ||
| Q1 24 | $-220.2M | $21.2M |
| Q4 25 | -36.6% | 19.3% | ||
| Q3 25 | -91.2% | 26.8% | ||
| Q2 25 | -73.5% | 25.2% | ||
| Q1 25 | — | 24.9% | ||
| Q4 24 | — | 18.1% | ||
| Q3 24 | — | 30.3% | ||
| Q2 24 | — | 25.4% | ||
| Q1 24 | -104.3% | 19.1% |
| Q4 25 | 0.0% | 0.6% | ||
| Q3 25 | 0.4% | 0.7% | ||
| Q2 25 | 0.5% | 0.4% | ||
| Q1 25 | 0.0% | 0.9% | ||
| Q4 24 | — | 0.5% | ||
| Q3 24 | — | 0.5% | ||
| Q2 24 | — | 0.4% | ||
| Q1 24 | 0.3% | 0.9% |
| Q4 25 | — | 0.15× | ||
| Q3 25 | — | 3.55× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BBIO
Segment breakdown not available.
PD
| US | $88.8M | 71% |
| Non Us | $35.7M | 29% |
